Tweets
#ACR18 poster 1265:
Gout management in primary care can be improved with a thoughtful structured approach. Quantity and quality of ULT improves; proportion failing to meet SUA target fell from 64% to 39%. Exemplary approach to gout care.
@RheumNow https://t.co/GeE5RRU0Pr
ǝlʇʇıɥʍ ɯɐs @samwhittle ( View Tweet )
7 years 9 months ago
Almost time for one of my perennial ACR favourites: Tech Tools for Rheumatology by @DrBhana
#ACR18 https://t.co/Loe9C16WlO
ǝlʇʇıɥʍ ɯɐs @samwhittle ( View Tweet )
7 years 9 months ago
Good to see a virtual appearance by @RonanTKavanagh here at #ACR18, via @DrBhana’s excellent presentation. https://t.co/fxqFnYO8jr
ǝlʇʇıɥʍ ɯɐs @samwhittle ( View Tweet )
7 years 9 months ago
.@BrennanSpiegel Digital sensors are now available for multiple organ systems #ACR18 @RheumNow https://t.co/RFMA9eArbt
Suleman Bhana, MD @DrBhana ( View Tweet )
7 years 9 months ago
Numbers just released - 15,000 attendees at #ACR18 from 106 countries
Felicity Nelson @frogsandstars ( View Tweet )
7 years 9 months ago
Well done to our outstanding former registrar Bess Leonardo for her excellent work that was presented at #ACR18 today (poster 2353), looking at how RA patients access information about MTX. https://t.co/PF0BNQpdKl
ǝlʇʇıɥʍ ɯɐs @samwhittle ( View Tweet )
7 years 9 months ago
2018 Great Debate examines questions about hydroxychloroquine dosing guidelines https://t.co/ltOnUmtrzw
ǝlʇʇıɥʍ ɯɐs @samwhittle ( View Tweet )
7 years 9 months ago
This enjoyable #ACR18 #fibromyalgia session is an appropriate time for a couple of periodic reminders:
1. Pain is an output of the brain (not an input)
2. Fibromyalgia is best conceptualised as a *description*, not an *explanation*
ǝlʇʇıɥʍ ɯɐs @samwhittle ( View Tweet )
7 years 9 months ago
#Vasculitis oral abstract session at #ACR18: back to back abstracts on use of #leflunomide for #GCA and #PMR. Promising results on efficacy and #steroid sparing effect. Could it become a standard alternative when tocilizumab contraindicated or not available?
Angelo Gaffo @ALGaffoRheumMD ( View Tweet )
7 years 9 months ago
#ACR18 #2923: Persistence of bone marrow oedema within the same SIJ quadrant associated with structural damage at 5 years in patients with early axial SpA.
@RheumNow
ǝlʇʇıɥʍ ɯɐs @samwhittle ( View Tweet )
7 years 9 months ago
#ACR18 #2924 - Great work by the always-impressive Sofia Ramiro using DESIR data in early AxSpA. Early progression (2-5yrs) of syndesmophytes predicted by baseline inflammation (MRI) and damage (XR).
@RheumNow https://t.co/D9aGXFUtcd
ǝlʇʇıɥʍ ɯɐs @samwhittle ( View Tweet )
7 years 9 months ago
#ACR18 #2952 - Validation of a clinical risk score for NSAID toxicity. Most patients fall into intermediate category, but 5% low risk, 25% high risk: probably useful in clinic if externally validated & calculator were available at point of care.
@RheumNow https://t.co/DjdaYLwuX3
ǝlʇʇıɥʍ ɯɐs @samwhittle ( View Tweet )
7 years 9 months ago
#ACR18 #2954 Brave presentation from Dr Jin under pressure from a feisty Jim O’Dell in the audience. Analysis of US claims database regarding combo Rx for RA. Only 3% of MTX combo is triple therapy (cf MTX+TNFi). No evidence for change over time.
@RheumNow
ǝlʇʇıɥʍ ɯɐs @samwhittle ( View Tweet )
7 years 9 months ago
#ACR18 #2956 Interesting UK CPRD data on opioid prescribing presented by @MeghnaJani - UK prescribers seem to be getting the message about opioids, but work still to be done (esp regarding use of strong opioids, with are hard to transition off).
@RheumNow https://t.co/LwyVVVfw8i
ǝlʇʇıɥʍ ɯɐs @samwhittle ( View Tweet )
7 years 9 months ago
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Novartis. All content chosen and distributed by RheumNow and its faculty.
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
